There have been about 25 representations received regarding the human papilloma virus (HPV) vaccine, Gardasil.
The Joint Committee on Vaccination and Immunisation (JCVI) is in the process of thoroughly examining the vaccine safety, efficacy and cost-effectiveness evidence concerning HPV vaccines. The work is being taken forward by a sub-group of JCVI, with further work ongoing to evaluate whether the vaccine is considered to be a cost-effective prevention of cervical cancer; and the impact that HPV vaccine may have on genital warts.
The sub group’s advice will be reported to the main JCVI committee for further discussion.
No decisions will be taken on introducing these vaccines into the immunisation programme until JCVI has presented its advice to Ministers for their consideration.